Moreover, when the patients with stage-III MM lacking DEK expression were excluded from the data, expression levels of DEK in the rest of the stage-III patient samples was significantly lower than those of healthy controls (P = 0.0006 (for DEK/ABL1) and P = 0.0096 (for DEK/ACTB)) and patients with stage-I/stage-II MM (P = 0.0035 for DEK/ABL1 and P = 0.0036 for DEK/ACTB)) (Fig 1A and 1B). This evidence concerns the gene ABL1 and Miyoshi myopathy.